SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
----------------
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934
DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED): MARCH 1ST, 2005
----------------
AMERSIN LIFE SCIENCES CORPORATION.
(EXACT NAME OF REGISTRANT AS SPECIFIED IN ITS CHARTER)
NEVADA 0-25553 88-0419476
(State or other jurisdiction of (Commission file (IRS employer
incorporation) number) identification number)
410 PARK AVENUE, 15TH FLOOR, NEW YORK, NY 10022
(Address of principal executive offices) (Zip code)
Registrant's telephone, including area code (604) 881-2899
N/A
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the
following provisions (see General Instruction A.2. below):
[_] Written communications pursuant to Rule 425 under the Securities Act
(17 CFR 230.425)
[_] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17
CFR 240.14a-12)
[_] Pre-commencement communications pursuant to Rule 14d-2(b) under the
Exchange Act (17 CFR 240.14d-2(b))
[_] Pre-commencement communications pursuant to Rule 13e-4(c) under the
Exchange Act (17 CFR 240.13e-4(c))
- --------------------------------------------------------------------------------
ITEM 5.02 ELECTION OF DIRECTORS
On March 1st, 2005 the Chairman of the board nominated, and the board of
directors voted unanimously to appoint, Mr. (Harry) Zhihao Jin to the board of
directors. There is no understanding between Mr. Jin and any other person
pursuant to which he was selected as a director. Mr. Jin has not been named,
and is currently not under consideration, to serve on any committees. There is
no indebtedness or any related party transactions or business relations to be
disclosed with respect to Mr. Jin.
A copy of the news release announcing the appointment of Mr. Jin is attached
hereto as Exhibit 99.1.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
AMERSIN LIFE SCIENCES CORPORATION.
(Registrant)
DATE: March 1st, 2005
By: /s/ H. Y. (Reid) Li
-------------------
H. Y. (Reid) Li
President and Chief Executive Officer
2